Jamere Jackson - Eli Lilly Independent Director

LLY
 Stock
  

USD 323.35  6.66  2.02%   

  Director
Mr. Jamere Jackson is an Independent Director of the Company. He brings to the board significant global financial expertise and strong background in strategic planning, having spent his professional career in a broad range of financial and strategic planning roles. He is an audit committee financial expert, based on his CFO experience and his training as a certified public accountant.
Age: 52  Director Since 2016      
317 276 2000  https://www.lilly.com
Jackson brings to the board significant global financial expertise and strong background in strategic planning, having spent his professional career in a broad range of financial and strategic planning roles. He is an audit committee financial expert, based on his CFO experience and his training as a certified public accountant.

Eli Lilly Management Efficiency

Eli Lilly And has Return on Asset of 12.12 % which means that on every $100 spent on asset, it made $12.12 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 74.02 %, implying that it generated $74.02 on every 100 dollars invested. Eli Lilly management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 16.55 B in debt with debt to equity (D/E) ratio of 1.75, which is OK given its current industry classification. Eli Lilly And has a current ratio of 1.24, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Debt can assist Eli Lilly until it has trouble settling it off, either with new capital or with free cash flow. So, Eli Lilly's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eli Lilly And sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eli Lilly to invest in growth at high rates of return. When we think about Eli Lilly's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

DIRECTOR Since

Thomas AlbergAmazon Inc
2011
Wendell WeeksAmazon Inc
2016
Patricia StonesiferAmazon Inc
2017
Jamie GorelickAmazon Inc
2012
Judith McGrathAmazon Inc
2014
Thomas RyderAmazon Inc
2011
John BrownAmazon Inc
2004
William GordonAmazon Inc
2003
Daniel HuttenlocherAmazon Inc
2016
Rosalind BrewerAmazon Inc
2019
Indra NooyiAmazon Inc
2019
Jonathan RubinsteinAmazon Inc
2010
Tom AlbergAmazon Inc
2016
Alain MonieAmazon Inc
2008
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 35000 people. Eli Lilly And (LLY) is traded on New York Stock Exchange in USA and employs 35,000 people.

Eli Lilly And Leadership Team

Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli Lilly. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ralph Alvarez, Independent Director
Jamere Jackson, Independent Director
Johna Norton, Senior Vice President - Global Quality
Juan Luciano, Lead Independent Director
J Fyrwald, Independent Director
Alfonso Zulueta, Senior Vice President and President - Emerging Markets business
Anne White, Senior Vice President and Presidentident - Lilly Oncology
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Patrik Jonsson, Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA
Karen Walker, Independent Director
Ilya Yuffa, Senior Vice President and President of Lilly Bio-Medicines
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Raul Alvarez, Independent Director
Marschall Runge, Independent Director
Myles ONeill, Senior Vice President and President - Manufacturing Operations
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Daniel Skovronsky, Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories
Edgardo Hernandez, Senior Vice President and Presidentident - Manufacturing Operations
Carolyn Bertozzi, Independent Director
Erik Fyrwald, Independent Director
Franklyn Prendergast, Independent Director
Ellen Marram, Lead Independent Director
Kathi Seifert, Independent Director
Joshua Smiley, Chief Financial Officer, Senior Vice President
Anat Hakim, Senior Vice President, General Counsel, Secretary
Fionnuala Walsh, Senior Vice President - Global Quality
Alonzo Weems, Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Gabrielle Sulzberger, Independent Director
Anat Ashkenazi, Chief Financial Officer, Senior Vice President
Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health
John Lechleiter, Chairman, CEO and Pres
Karen Horn, Independent Director
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Darren Carroll, Senior Vice President - Corporate Business Development
William Kaelin, Independent Director
Jacob Naarden, Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology
Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines
Barton Peterson, Senior Vice President - Corporate Affairs and Communications
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee
Kimberly Johnson, Independent Director
Michael Harrington, Executive Vice President, General Counsel
David Hoover, Independent Director
Maria Crowe, President - Manufacturing Operations
Diogo Rau, Senior Vice President Chief Information and Digital Officer
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories
Aarti Shah, Senior Vice President - Chief Information and Digital Officer
Susan Mahony, Senior Vice President and President - Lilly Oncology
Jackson Tai, Independent Director
Michael Eskew, Independent Director
Katherine Baicker, Independent Director
Stephen Fry, Senior Vice President - Human Resources and Diversity
Michael Mason, Senior Vice President and President Lilly Diabetes

Eli Lilly Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Eli Lilly Implied Volatility

    
  40.85  
Eli Lilly's implied volatility exposes the market's sentiment of Eli Lilly And stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Eli Lilly's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Eli Lilly stock will not fluctuate a lot when Eli Lilly's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Eli Lilly And using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Eli Lilly And price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli Lilly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli Lilly that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine Eli Lilly value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.